Does Mark Cuban's Cost Plus Drug Company offer better savings than GoodRx for dermatology medications?
🔍 Key Finding
Mark Cuban Cost Plus Drug Company (CostPlus) offers significantly greater cost savings for dermatology medications compared to GoodRx, even when accounting for shipping fees.
🔬 Methodology Overview
Design: Observational cost-analysis comparing medication prices
Data collection: Prices extracted on November 26, 2023
Medications: 15 commonly prescribed dermatology medications selected from Dobkin and Zirwas study
Comparison points: CostPlus prices (with and without shipping) vs. GoodRx prices from New York, Los Angeles, and Chicago
Analysis: Wilcoxon signed rank exact tests using RStudio V1.4.1106
📊 Evidence
Average medication cost: $17 (SE $3.22) through CostPlus vs. $31.21 (SE $6.42) through GoodRx (P<.001)
CostPlus with $2.60 shipping: $19.60 (SE $3.22) - still significantly lower than GoodRx (P<.001)
CostPlus with $5 shipping: $22 (SE $3.22) - still significantly lower than GoodRx (P=.007)
Average retail cost of medications: $147.23 (SE $36.54)
CostPlus average savings: $130.23 (SE $33.78) or 81% off retail
GoodRx average savings: $116.01 (SE $30.73) or 70% off retail
💡 Clinical Impact
CostPlus offers a viable tool to reduce prescription medication burden within dermatology, especially for uninsured patients or those with high-deductible health plans, while also providing the convenience of shipping all prescriptions directly to patients.
🤔 Limitations
Observational design with drug prices measured at only a single time point
Did not fully assess the impact of ordering multiple medications at once
Did not assess prices from compounding pharmacies, which often offer discounted prices
Limited generalizability as CostPlus is the first of its kind in the United States
Certain common dermatology medications (tretinoin, calcipotriene) are not available on CostPlus
Youn CG, Kim JY, Yang VB, Bae GH. Improving Affordability in Dermatology: Cost Savings in Mark Cuban Cost Plus Drug Company Versus GoodRx. JMIR Dermatol 2024;7